| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
|
Am J Med
|
2006
|
2.87
|
|
2
|
Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo.
|
Clin Gastroenterol Hepatol
|
2005
|
2.50
|
|
3
|
Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
|
Am J Cardiol
|
2002
|
2.38
|
|
4
|
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
|
Arch Intern Med
|
2005
|
1.72
|
|
5
|
Efficacy of celecoxib, a COX-2-specific inhibitor, and naproxen in the management of acute ankle sprain: results of a double-blind, randomized controlled trial.
|
Clin J Sport Med
|
2004
|
1.59
|
|
6
|
Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.
|
Arthritis Rheum
|
2003
|
1.54
|
|
7
|
Alvimopan, for postoperative ileus following bowel resection: a pooled analysis of phase III studies.
|
Ann Surg
|
2007
|
1.46
|
|
8
|
Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway.
|
Arch Surg
|
2008
|
1.43
|
|
9
|
Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor.
|
Anesth Analg
|
2004
|
1.09
|
|
10
|
A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy.
|
Am J Obstet Gynecol
|
2006
|
0.97
|
|
11
|
Preoperative parenteral parecoxib and follow-up oral valdecoxib reduce length of stay and improve quality of patient recovery after laparoscopic cholecystectomy surgery.
|
Anesth Analg
|
2004
|
0.88
|
|
12
|
The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials.
|
Ann Rheum Dis
|
2006
|
0.85
|
|
13
|
Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials.
|
Curr Med Res Opin
|
2011
|
0.84
|
|
14
|
Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: a multicenter, double-blind, randomized controlled trial in acute ankle sprain.
|
Am J Orthop (Belle Mead NJ)
|
2002
|
0.81
|
|
15
|
A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials.
|
Ann Med
|
2011
|
0.80
|
|
16
|
Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers.
|
Curr Med Res Opin
|
2011
|
0.77
|
|
17
|
Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.
|
Am Heart J
|
2012
|
0.77
|
|
18
|
Onset and durability of pain relief in knee osteoarthritis: Pooled results from two placebo trials of naproxen/esomeprazole combination and celecoxib.
|
Phys Sportsmed
|
2015
|
0.76
|
|
19
|
Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
|
J Rheumatol
|
2005
|
0.75
|
|
20
|
Letter by Fort and Plachetka regarding article, "association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from PLATO".
|
Circulation
|
2012
|
0.75
|
|
21
|
Aspirin Use in Secondary Cardiovascular Protection and the Development of Aspirin-Associated Erosions and Ulcers.
|
J Cardiovasc Pharmacol
|
2016
|
0.75
|